AU2011271479B2 - Compositions and methods for modulating the Wnt signaling pathway - Google Patents

Compositions and methods for modulating the Wnt signaling pathway Download PDF

Info

Publication number
AU2011271479B2
AU2011271479B2 AU2011271479A AU2011271479A AU2011271479B2 AU 2011271479 B2 AU2011271479 B2 AU 2011271479B2 AU 2011271479 A AU2011271479 A AU 2011271479A AU 2011271479 A AU2011271479 A AU 2011271479A AU 2011271479 B2 AU2011271479 B2 AU 2011271479B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
mmol
pct
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2011271479A
Other languages
English (en)
Other versions
AU2011271479A1 (en
Inventor
Dai Cheng
Wenqi Gao
Dong Han
Rajender Reddy Leleti
Shifeng Pan
Lichun Shen
Guobao Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Novartis AG
Original Assignee
IRM LLC
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011271479(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by IRM LLC, Novartis AG filed Critical IRM LLC
Publication of AU2011271479A1 publication Critical patent/AU2011271479A1/en
Application granted granted Critical
Publication of AU2011271479B2 publication Critical patent/AU2011271479B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2011271479A 2010-06-29 2011-06-28 Compositions and methods for modulating the Wnt signaling pathway Expired - Fee Related AU2011271479B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35956910P 2010-06-29 2010-06-29
US61/359,569 2010-06-29
PCT/US2011/042215 WO2012003189A1 (en) 2010-06-29 2011-06-28 Compositions and methods for modulating the wnt signaling pathway

Publications (2)

Publication Number Publication Date
AU2011271479A1 AU2011271479A1 (en) 2013-02-07
AU2011271479B2 true AU2011271479B2 (en) 2014-08-14

Family

ID=44514972

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011271479A Expired - Fee Related AU2011271479B2 (en) 2010-06-29 2011-06-28 Compositions and methods for modulating the Wnt signaling pathway

Country Status (27)

Country Link
US (1) US9181235B2 (cg-RX-API-DMAC7.html)
EP (1) EP2588453B1 (cg-RX-API-DMAC7.html)
JP (1) JP5778270B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130131290A (cg-RX-API-DMAC7.html)
CN (1) CN102958917B (cg-RX-API-DMAC7.html)
AR (1) AR082029A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011271479B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012033350A2 (cg-RX-API-DMAC7.html)
CA (1) CA2803879A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012003604A1 (cg-RX-API-DMAC7.html)
CO (1) CO6650353A2 (cg-RX-API-DMAC7.html)
CU (1) CU20120174A7 (cg-RX-API-DMAC7.html)
DO (1) DOP2012000329A (cg-RX-API-DMAC7.html)
EA (1) EA201390032A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012410A (cg-RX-API-DMAC7.html)
ES (1) ES2536216T3 (cg-RX-API-DMAC7.html)
MA (1) MA34388B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012015092A (cg-RX-API-DMAC7.html)
NI (1) NI201200190A (cg-RX-API-DMAC7.html)
PE (1) PE20130311A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012502571A1 (cg-RX-API-DMAC7.html)
SG (1) SG186473A1 (cg-RX-API-DMAC7.html)
TN (1) TN2012000575A1 (cg-RX-API-DMAC7.html)
TW (1) TW201206921A (cg-RX-API-DMAC7.html)
UY (1) UY33469A (cg-RX-API-DMAC7.html)
WO (1) WO2012003189A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201300319B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US7982013B2 (en) 2008-09-26 2011-07-19 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
AU2011235904B2 (en) 2010-04-01 2015-10-08 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
TWI567061B (zh) * 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
RU2486859C1 (ru) * 2012-02-02 2013-07-10 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения и социального развития Российской Федерации Способ оценки эффективности комбинированного органосохраняющего лечения первичной начальной ретинобластомы у детей
BR112014031263B1 (pt) 2012-06-15 2022-03-29 Curegenix Inc Composto, composição farmacêutica, método de inibição da secreção wnt, método de inibição da sinalização wnt e uso de um composto
JP2015536933A (ja) * 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
ES2684360T3 (es) * 2013-11-01 2018-10-02 Novartis Ag Aminoheteroaril benzamidas como inhibidores de quinasa
AU2015329784C1 (en) * 2014-10-08 2020-10-15 Redx Pharma Plc N-pyridinyl acetamide derivatives as inhibitors of the Wnt signalling pathway
PT3204381T (pt) * 2014-10-08 2022-07-18 Redx Pharma Plc Derivados de n-piridinil acetamida como inibidores da via de sinalização wnt
CN104557862B (zh) * 2014-12-15 2017-05-17 苏州云轩医药科技有限公司 具有Wnt信号通路抑制活性的杂环化合物
EA201791737A1 (ru) 2015-02-03 2018-03-30 КАДМОН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Стабильные составы триентина
WO2016168524A1 (en) * 2015-04-15 2016-10-20 University Of Utah Research Foundation Substituted n-([1,1'-biphenyl]-3-yl)-[1,1'-biphenyl]-3-carboxamide analogs as inhibitors for beta-catenin/b-cell lymphoma 9 interactions
CA2985813A1 (en) * 2015-05-26 2016-12-01 Curegenix Corporation Tumor biomarkers and use thereof
CN107759584B (zh) * 2016-08-16 2021-06-01 苏州云轩医药科技有限公司 一种具有Wnt信号通路抑制活性的氨基五元杂环化合物及其应用
CN107056754B (zh) * 2015-12-07 2020-12-04 苏州信诺维医药科技有限公司 内嵌脲类结构的wnt通路抑制剂
KR102214225B1 (ko) * 2015-12-07 2021-02-10 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. 5원 헤테로시클릭 아미드계 wnt 경로 억제제
US11542254B2 (en) 2016-03-25 2023-01-03 Universisity Of Utah Research Foundation Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors
US10793544B2 (en) * 2016-09-01 2020-10-06 The Board Of Regents Of The University Of Texas System Disubstituted and trisubstituted 1,2,3-triazoles as Wnt inhibitors
WO2019106156A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
EP3717465A1 (en) * 2017-11-30 2020-10-07 Step Pharma S.A.S. Compounds
WO2019124603A1 (ko) * 2017-12-22 2019-06-27 경상대학교병원 Iwr-1을 유효성분으로 함유하는 켈로이드 예방 또는 치료용 조성물
PE20251292A1 (es) 2018-03-08 2025-05-14 Incyte Corp Compuestos diolicos de aminopirazina como inhibidores de pi3k-gamma
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN111662228B (zh) * 2019-03-07 2023-07-28 中国医学科学院药物研究所 吡啶酮酰联芳基胺类化合物及其用途
US12466810B2 (en) 2019-06-04 2025-11-11 Step Pharma S.A.S. N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
CA3239071A1 (en) 2021-11-25 2023-06-01 Fanglong Yang Chimeric compound for targeted degradation of androgen receptor protein, preparation method therefor, and medical use thereof
US20230399299A1 (en) * 2022-06-14 2023-12-14 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046117A1 (en) * 2002-11-19 2004-06-03 Aventis Pharma Deutschland Gmbh Pyridazinone derivatives as gsk-3beta inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
EP1501514B1 (en) * 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US20080275062A1 (en) * 2004-01-30 2008-11-06 David Harold Drewry Chemical Compounds
CA2637620A1 (en) * 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
KR20090060334A (ko) * 2006-09-08 2009-06-11 제넨테크, 인크. Ｗｎｔ 길항제 및 ｗｎｔ-매개 장애의 진단 및 치료에서의 이의 용도
EP2215049B1 (en) 2007-10-31 2019-06-12 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
AU2008335709A1 (en) 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
AU2009225869B2 (en) * 2008-03-18 2014-01-23 Merck Sharp & Dohme Llc Substituted 4-hydroxypyrimidine-5-carboxamides
EP2303862B1 (en) * 2008-05-27 2016-08-24 The Board of Regents of The University of Texas System Wnt protein signalling inhibitors
US8384140B2 (en) 2008-07-29 2013-02-26 International Business Machines Corporation Structure for dual contact trench capacitor and structure thereof
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046117A1 (en) * 2002-11-19 2004-06-03 Aventis Pharma Deutschland Gmbh Pyridazinone derivatives as gsk-3beta inhibitors

Also Published As

Publication number Publication date
CO6650353A2 (es) 2013-04-15
AU2011271479A1 (en) 2013-02-07
CN102958917B (zh) 2014-10-08
MX2012015092A (es) 2013-03-05
KR20130131290A (ko) 2013-12-03
DOP2012000329A (es) 2013-07-15
TW201206921A (en) 2012-02-16
US9181235B2 (en) 2015-11-10
CA2803879A1 (en) 2012-01-05
CN102958917A (zh) 2013-03-06
AR082029A1 (es) 2012-11-07
SG186473A1 (en) 2013-02-28
WO2012003189A1 (en) 2012-01-05
JP2013533879A (ja) 2013-08-29
BR112012033350A2 (pt) 2016-11-29
MA34388B1 (fr) 2013-07-03
PE20130311A1 (es) 2013-03-23
ECSP13012410A (es) 2013-03-28
JP5778270B2 (ja) 2015-09-16
US20130079328A1 (en) 2013-03-28
UY33469A (es) 2012-01-31
CU20120174A7 (es) 2013-04-19
ES2536216T3 (es) 2015-05-21
NI201200190A (es) 2013-04-15
EP2588453B1 (en) 2015-04-01
TN2012000575A1 (en) 2014-04-01
CL2012003604A1 (es) 2013-03-22
EA201390032A1 (ru) 2013-06-28
PH12012502571A1 (en) 2020-10-19
ZA201300319B (en) 2014-10-29
EP2588453A1 (en) 2013-05-08

Similar Documents

Publication Publication Date Title
AU2011271479B2 (en) Compositions and methods for modulating the Wnt signaling pathway
CA2753552C (en) N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators
JP6078640B2 (ja) Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
MX2011004570A (es) Antagonistas del receptor p2x3 para el tratamiento del dolor.
AU2012203023C1 (en) N-(hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as Wnt signaling modulators
HK1182392A (en) N-(hetero)aryl,2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
HK1160464B (en) N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee